Seragon’s SRN-901: Breakthrough Aging Intervention Drug Achieves Dramatic Lifespan Extension in Preclinical Study
In a May 7, 2024 press release, Seragon Biosciences announced that its aging intervention drug candidate, SRN-901, achieved one of the largest extensions of
